Arthur A. Levin is Director at Avidity Biosciences, Inc. (RNA). They have made 9 open-market trades across 2 companies since 2006, most recently 2026-03-13.
CIK 0001181556
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STOK | SELL · 10b5-1 | 2026-03-13 | 2026-03-17 | $36.80 | $22K | +0.0% | +7.6% | -8.6% |
| RNA | SELL · 10b5-1 | 2026-01-21 | 2026-01-23 | $72.45 | $127K | +0.2% | +0.5% | -80.9% |
| RNA | SELL · 10b5-1 | 2025-08-06 | 2025-08-08 | $47.62 | $5.1M | -0.3% | +8.1% | +57.0% |
| RNA | SELL · 10b5-1 | 2025-01-21 | 2025-01-23 | $28.60 | $107K | +12.2% | +2.7% | +3.2% |
| RNA | SELL · 10b5-1 | 2024-11-19 | 2024-11-20 | $42.12 | $280K | -12.3% | -27.5% | -27.0% |
| RNA | SELL · 10b5-1 | 2024-10-21 | 2024-10-23 | $46.63 | $233K | -1.4% | -4.9% | -32.2% |
| RNA | SELL · 10b5-1 | 2024-09-19 | 2024-09-20 | $45.73 | $457K | +7.1% | +6.2% | -29.4% |
| RNA | SELL · 10b5-1 | 2024-08-19 | 2024-08-21 | $45.19 | $226K | -9.6% | -1.9% | -4.6% |
| RNA | SELL · 10b5-1 | 2024-07-19 | 2024-07-23 | $45.01 | $225K | -8.8% | -5.3% | +3.2% |
| RNA | SELL · 10b5-1 | 2024-06-20 | 2024-06-21 | $37.59 | $376K | -3.9% | +19.5% | +17.8% |
| RNA | SELL · 10b5-1 | 2024-06-12 | 2024-06-14 | $38.08 | $3.8M | +3.1% | +16.0% | +5.0% |
| RNA | SELL · 10b5-1 | 2024-05-20 | 2024-05-21 | $29.90 | $150K | -8.5% | +27.9% | +54.4% |
| RNA | SELL · 10b5-1 | 2024-04-19 | 2024-04-22 | $22.82 | $114K | +5.7% | +22.4% | +91.3% |
| RNA | SELL · 10b5-1 | 2024-04-03 | 2024-04-03 | $27.11 | $542K | -10.9% | -1.5% | +44.5% |
| RNA | SELL · 10b5-1 | 2024-03-19 | 2024-03-21 | $23.97 | $120K | +9.7% | -0.5% | +54.8% |
| RNA | SELL · 10b5-1 | 2024-03-12 | 2024-03-12 | $22.04 | $609K | +5.7% | +13.1% | +20.9% |
| RNA | SELL · 10b5-1 | 2024-01-22 | 2024-01-23 | $10.13 | $19K | +13.9% | +42.4% | +136.6% |
| RNA | SELL · 10b5-1 | 2023-03-15 | 2023-03-17 | $22.01 | $2K | -1.0% | -20.6% | -38.8% |
| RNA | SELL | 2023-02-14 | 2023-02-15 | $23.64 | $460K | -3.1% | -16.1% | -55.2% |
| RNA | SELL | 2023-01-12 | 2023-01-17 | $22.00 | $220K | +6.3% | +9.3% | -26.7% |
| RNA | SELL | 2022-12-29 | 2023-01-03 | $22.01 | $1.8M | +12.3% | +20.2% | -23.7% |
| RNA | SELL | 2022-08-12 | 2022-08-31 | $22.11 | $3.2M | +1.6% | -16.2% | -40.7% |
| RNA | SELL | 2021-11-18 | 2021-11-22 | $27.89 | $697K | -10.9% | -6.2% | -39.1% |
| RNA | SELL | 2021-06-24 | 2021-06-28 | $28.12 | $1.1M | -3.8% | -20.8% | -11.1% |
| RNA | SELL · 10b5-1 | 2021-06-17 | 2021-06-22 | $27.75 | $6K | -5.4% | -7.0% | -4.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.